Fluorescence spectroscopic and molecular docking studies of the binding interaction between the new anaplastic lymphoma kinase inhibitor crizotinib and bovine serum albumin

Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy

Volumn 171, Issue , 2017, Pages 174-182

  Abdelhameed, Ali S ^a   Alanazi, Amer M ^a   Bakheit, Ahmed H ^a   Darwish, Hany W ^a,b   Ghabbour, Hazem A ^a,c   Darwish, Ibrahim A ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b CAIRO UNIVERSITY   (Egypt)

^c MANSOURA UNIVERSITY   (Egypt)

Author keywords

Bovine serum albumin; Crizotinib; Fluorescence spectroscopy; Molecular docking

Indexed keywords

BINDING ENERGY; BINS; FLUORESCENCE; FLUORESCENCE SPECTROSCOPY; MAMMALS; MOLECULAR MODELING; SURFACE PLASMON RESONANCE;

ANAPLASTIC LYMPHOMA KINASE; BOVINE SERUM ALBUMINS; COMPETITIVE EXPERIMENTS; CRIZOTINIB; MOLECULAR DOCKING; PHYSIOLOGICAL CONDITION; SYNCHRONOUS FLUORESCENCE; THERMODYNAMIC PARAMETER;

BODY FLUIDS;

ANAPLASTIC LYMPHOMA KINASE; BOVINE SERUM ALBUMIN; CRIZOTINIB; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING COMPETITION; BINDING SITE; BOVINE; CHEMISTRY; METABOLISM; MOLECULAR DOCKING; PROTEIN CONFORMATION; SPECTROFLUOROMETRY; THERMODYNAMICS; ULTRAVIOLET SPECTROPHOTOMETRY;

ANIMALS; BINDING SITES; BINDING, COMPETITIVE; CATTLE; MOLECULAR DOCKING SIMULATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SERUM ALBUMIN, BOVINE; SPECTROMETRY, FLUORESCENCE; SPECTROPHOTOMETRY, ULTRAVIOLET; THERMODYNAMICS;

EID: 84981484197     PISSN: 13861425     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.saa.2016.08.005     Document Type: Article

References (47)

1. [1] Jemal, A., Siegel, R., Xu, J., Ward, E., Cancer statistics, 2010. CA Cancer J. Clin. 60 (2010), 277–300.
2. [2] Roberts, P.J., Clinical use of crizotinib for the treatment of non-small cell lung cancer. Biologics Targets Ther. 7 (2013), 91–101.
3. [3] Ou, S., Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des. Dev. Ther. 5 (2011), 471–485.
4. [4] Rodig, S.J., Shapiro, G.I., Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr. Opin. Investig. Drugs (Lond. Engl. 11:2010 (2000), 1477–1490.
5. [5] Kwak, E.L., Bang, Y.-J., Camidge, D.R., Shaw, A.T., Solomon, B., Maki, R.G., Ou, S.-H.I., Dezube, B.J., Jänne, P.A., Costa, D.B., Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer. N. Engl. J. Med. 363 (2010), 1693–1703.
6. [6] Cui, J.J., Tran-Dubé, M., Shen, H., Nambu, M., Kung, P.-P., Pairish, M., Jia, L., Meng, J., Funk, L., Botrous, I., Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal–epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J. Med. Chem. 54 (2011), 6342–6363.
7. [7] Kratz, F., Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control. Release 132 (2008), 171–183.
8. [8] Shi, J.-H., Chen, J., Wang, J., Zhu, Y.-Y., Wang, Q., Binding interaction of sorafenib with bovine serum albumin: spectroscopic methodologies and molecular docking. Spectrochim. Acta A Mol. Biomol. Spectrosc. 149 (2015), 630–637.
9. [9] Tian, J., Liu, J., Hu, Z., Chen, X., Interaction of wogonin with bovine serum albumin. Bioorg. Med. Chem. 13 (2005), 4124–4129.
10. [10] Bolel, P., Mahapatra, N., Halder, M., Optical spectroscopic exploration of binding of cochineal red a with two homologous serum albumins. J. Agric. Food Chem. 60 (2012), 3727–3734.
11. [11] Carter, D.C., Ho, J.X., Structure of serum albumin. Adv. Protein Chem. 45 (1994), 153–203.
12. [12] Han, X.-L., Tian, F.-F., Ge, Y.-S., Jiang, F.-L., Lai, L., Li, D.-W., Yu, Q.-L., Wang, J., Lin, C., Liu, Y., Spectroscopic, structural and thermodynamic properties of chlorpyrifos bound to serum albumin: a comparative study between BSA and HSA. J. Photochem. Photobiol. B Biol. 109 (2012), 1–11.
13. [13] Bujacz, A., Structures of bovine, equine and leporine serum albumin. Acta Crystallogr. D Biol. Crystallogr. 68 (2012), 1278–1289.
14. [14] Yu, X., Liao, Z., Jiang, B., Hu, X., Li, X., Spectroscopic analyses on interaction of bovine serum albumin with novel spiro [cyclopropane-pyrrolizin]. Spectrochim. Acta A Mol. Biomol. Spectrosc. 137 (2015), 129–136.
15. [15] Abdelhameed, A.S., Alanazi, A.M., Kadi, A.A., Spectrofluorimetric study of finasteride and bovine serum albumin interaction and its application for quantitative determination of finasteride in tablet dosage form. Anal. Methods, 2015.
16. [16] Abdelhameed, A.S., Insight into the interaction between the HIV-1 integrase inhibitor elvitegravir and bovine serum albumin: a spectroscopic study. J. Spectrosc., 2015, 2015.
17. [17] Shen, G.-F., Liu, T.-T., Wang, Q., Jiang, M., Shi, J.-H., Spectroscopic and molecular docking studies of binding interaction of gefitinib, lapatinib and sunitinib with bovine serum albumin (BSA). J. Photochem. Photobiol. B Biol. 153 (2015), 380–390.
18. [18] Alanazi, A.M., Abdelhameed, A.S., A spectroscopic approach to investigate the molecular interactions between the newly approved irreversible ErbB blocker “afatinib” and bovine serum albumin. PloS one, 11, 2016.
19. [19] Dufour, C., Dangles, O., Flavonoid–serum albumin complexation: determination of binding constants and binding sites by fluorescence spectroscopy. Biochim. Biophys. Acta Gen. Subj. 1721 (2005), 164–173.
20. [20] Lakowicz, J.R., Principles of Fluorescence Spectroscopy. 2007, Springer Science & Business Media.
21. [21] Bujacz, A., Structures of bovine, equine and leporine serum albumin. Acta Crystallogr., Sect. D: Biol. Crystallogr. 68 (2012), 1278–1289.
22. [22] Molegro, A., MVD 5.0 Molegro Virtual Docker, DK-8000. 2011, Aarhus C, Denmark.
23. [23] Ultra, C., Suite Kerwin, Sean M. J. Am. Chem. Soc. 132 (2010), 2466–2467.
24. [24] Pasban Ziyarat, F., Asoodeh, A., Sharif Barfeh, Z., Pirouzi, M., Chamani, J., Probing the interaction of lysozyme with ciprofloxacin in the presence of different-sized Ag nano-particles by multispectroscopic techniques and isothermal titration calorimetry. J. Biomol. Struct. Dyn. 32 (2014), 613–629.
25. [25] Bourassa, P., Bariyanga, J., Tajmir-Riahi, H.A., Binding sites of resveratrol, Genistein, and curcumin with milk α- and β-caseins. J. Phys. Chem. B 117 (2013), 1287–1295.
26. [26] Hu, Y., Da, L., Insights into the selective binding and toxic mechanism of microcystin to catalase. Spectrochim. Acta A Mol. Biomol. Spectrosc. 121 (2014), 230–237.
27. [27] Lakowicz, J.R., Principle of Fluorescence Spectroscopy. second ed., 1999, Plemum Press, New York.
28. [28] Wang, H., Mao, J., Duan, A., Che, B., Wang, W., Ma, M., Wang, X., Fluorescence quenching of 4-tert-Octylphenol by room temperature ionic liquids and its application. J. Fluoresc. 23 (2013), 323–331.
29. [29] Chen, G.-Z., Huang, X.-Z., Xu, J.-G., Spectrofluorimetric Analytical Method. second ed., 1990, Science Press, Beijing.
30. [30] Wang, Y.Q., Zhang, H.M., Zhang, G.C., Tao, W.H., Fei, Z.H., Liu, Z.T., Spectroscopic studies on the interaction between silicotungstic acid and bovine serum albumin. J. Pharm. Biomed. Anal. 43 (2007), 1869–1875.
31. [31] Shcharbin, D., Klajnert, B., Mazhul, V., Bryszewska, M., Dendrimer interactions with hydrophobic fluorescent probes and human serum albumin. J. Fluoresc. 15 (2005), 21–28.
32. [32] Stern, O., Volmer, M., The extinction period of fluorescence. Phys. Z. 20 (1919), 183–188.
33. [33] Lineweaver, H., Burk, D., The determination of enzyme dissociation constants. J. Am. Chem. Soc. 56 (1934), 658–666.
34. [34] Huang, Y., Zhang, Z., Zhang, D., Lv, J., Flow-injection analysis chemiluminescence detection combined with microdialysis sampling for studying protein binding of drug. Talanta 53 (2001), 835–841.
35. [35] Lakowicz, J.R., Weber, G., Quenching of fluorescence by oxygen. Probe for structural fluctuations in macromolecules. Biochemistry 12 (1973), 4161–4170.
36. [36] Ware, W.R., Oxygen quenching of fluorescence in solution: an experimental study of the diffusion process. J. Phys. Chem. 66 (1962), 455–458.
37. [37] Liu, J., Tian, J.-n., Zhang, J., Hu, Z., Chen, X., Interaction of magnolol with bovine serum albumin: a fluorescence-quenching study. Anal. Bioanal. Chem. 376 (2003), 864–867.
38. [38] Forster, T., Sinanoglu, O., Modern Quantum Chemistry. 1996, Academic Press, New York.
39. [39] Rub, M.A., Khan, J.M., Asiri, A.M., Khan, R.H., ud-Din, K., Study on the interaction between amphiphilic drug and bovine serum albumin: a thermodynamic and spectroscopic description. J. Lumin. 155 (2014), 39–46.
40. [40] Ross, P.D., Subramanian, S., Thermodynamics of protein association reactions: forces contributing to stability. Biochemistry 20 (1981), 3096–3102.
41. [41] Liu, J., Tian, J., He, W., Xie, J., Hu, Z., Chen, X., Spectrofluorimetric study of the binding of daphnetin to bovine serum albumin. J. Pharm. Biomed. Anal. 35 (2004), 671–677.
42. [42] Chaturvedi, S.K., Ahmad, E., Khan, J.M., Alam, P., Ishtikhar, M., Khan, R.H., Elucidating the interaction of limonene with bovine serum albumin: a multi-technique approach. Mol. BioSyst. 11 (2015), 307–316.
43. [43] Yan, H., Zhao, S., Yang, J., Zhu, X., Dai, G., Liang, H., Pan, F., Weng, L., Interaction between levamisole hydrochloride and bovine serum albumin and the influence of alcohol: spectra. J. Solut. Chem. 38 (2009), 1183–1192.
44. [44] Zhang, H.-X., Huang, X., Mei, P., Gao, S., Interaction between Glyoxal-bis-(2-hydroxyanil) and bovine serum albumin in solution. J. Solut. Chem. 37 (2008), 631–640.
45. [45] Sułkowska, A., Interaction of drugs with bovine and human serum albumin. J. Mol. Struct. 614 (2002), 227–232.
46. [46] Ghuman, J., Zunszain, P.A., Petitpas, I., Bhattacharya, A.A., Otagiri, M., Curry, S., Structural basis of the drug-binding specificity of human serum albumin. J. Mol. Biol. 353 (2005), 38–52.
47. [47] Wei, J., Jin, F., Wu, Q., Jiang, Y., Gao, D., Liu, H., Molecular interaction study of flavonoid derivative 3d with human serum albumin using multispectroscopic and molecular modeling approach. Talanta 126 (2014), 116–121.